Healthcare provider profile · identity verified

Thomas M Bergren, DO

Internal Medicine · LAS VEGAS, NV · NPI 1770094153

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	561	206
Amlodipine Besylate	Amlodipine Besylate	375	140
Lisinopril	Lisinopril	309	113
Losartan Potassium	Losartan Potassium	282	95
Levothyroxine Sodium	Levothyroxine Sodium	269	91
Rosuvastatin Calcium	Rosuvastatin Calcium	266	94
Metformin Hcl	Metformin Hcl	238	98
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	175	35
Tamsulosin Hcl	Tamsulosin Hcl	167	71
Albuterol Sulfate Hfa	Albuterol Sulfate	159	62
Omeprazole	Omeprazole	159	61
Pantoprazole Sodium	Pantoprazole Sodium	159	63
Metoprolol Succinate	Metoprolol Succinate	144	56
Gabapentin	Gabapentin	143	66
Simvastatin	Simvastatin	141	49
Hydrochlorothiazide	Hydrochlorothiazide	121	49
Metoprolol Tartrate	Metoprolol Tartrate	120	41
Trazodone Hcl	Trazodone Hcl	108	42
Furosemide	Furosemide	107	51
Alendronate Sodium	Alendronate Sodium	106	39
Allopurinol	Allopurinol	102	38
Meloxicam	Meloxicam	102	39
Clopidogrel	Clopidogrel Bisulfate	92	33
Fluticasone Propionate	Fluticasone Propionate	89	42
Glipizide	Glipizide	88	33
Montelukast Sodium	Montelukast Sodium	79	32
Tizanidine Hcl	Tizanidine Hcl	79	28
Finasteride	Finasteride	71	26
Eliquis	Apixaban	69	19
Carvedilol	Carvedilol	66	31
Glimepiride	Glimepiride	66	24
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	64	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	64	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	63	22
Ibuprofen	Ibuprofen	58	27
Januvia	Sitagliptin Phosphate	56	14
Famotidine	Famotidine	54	25
Metformin Hcl Er	Metformin Hcl	54	15
Zolpidem Tartrate	Zolpidem Tartrate	54	13
Pioglitazone Hcl	Pioglitazone Hcl	50	19
Pravastatin Sodium	Pravastatin Sodium	49	14
Ozempic	Semaglutide	48	19
Potassium Chloride	Potassium Chloride	48	23
Pregabalin	Pregabalin	46	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	46	11
Atenolol	Atenolol	43	15
Symbicort	Budesonide/Formoterol Fumarate	43	12
Alprazolam	Alprazolam	42	12
Ezetimibe	Ezetimibe	39	13
Spironolactone	Spironolactone	38	15
Diclofenac Sodium	Diclofenac Sodium	37	17
Duloxetine Hcl	Duloxetine Hcl	36	14
Meclizine Hcl	Meclizine Hcl	36	13
Irbesartan	Irbesartan	34	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	34	suppressed
Buspirone Hcl	Buspirone Hcl	33	14
Escitalopram Oxalate	Escitalopram Oxalate	33	13
Valsartan	Valsartan	33	12
Hydralazine Hcl	Hydralazine Hcl	32	14
Hydroxyzine Hcl	Hydroxyzine Hcl	31	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	11
Jardiance	Empagliflozin	30	suppressed
Naproxen	Naproxen	28	11
Quetiapine Fumarate	Quetiapine Fumarate	28	12
Warfarin Sodium	Warfarin Sodium	27	suppressed
Baclofen	Baclofen	26	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Hydrocortisone	Hydrocortisone	26	suppressed
Prednisone	Prednisone	25	20
Sildenafil Citrate	Sildenafil Citrate	25	suppressed
Tramadol Hcl	Tramadol Hcl	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	18
Lorazepam	Lorazepam	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	11
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Clonazepam	Clonazepam	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	21	suppressed
Sodium Chloride	0.9 % Sodium Chloride	21	suppressed
Lovastatin	Lovastatin	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Folic Acid	Folic Acid	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	11
Clonidine Hcl	Clonidine Hcl	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Lactulose	Lactulose	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Ramipril	Ramipril	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Temazepam	Temazepam	12	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Fabrazyme	Agalsidase Beta	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error